Kazia Therapeutics Limited(NASDAQ:KZIA) 
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also dev...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 3.85
H 3.85
L 3.25
C 3.55
V 102,219
10EMA 3.55
20EMA 3.55
60EMA 3.55
120EMA 3.55
250EMA 3.55